Lucid Diagnostics reports real-world data from 12,000 esophageal tests

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced results from a study of nearly 12,000 patients who underwent its EsoGuard Esophageal DNA Test using the EsoCheck Esophageal Cell Collection Device between January 2023 and June 2024.

The 18-month retrospective analysis showed EsoCheck achieved a 95% technical success rate, with 95% of procedures completed in under two minutes and no serious adverse events reported. The study evaluated patients at risk for Barrett's esophagus, a precancerous condition of the esophagus.

The manuscript, titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients," is available on medRxiv while undergoing peer review for publication.

According to the study, the majority of patients met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening. The procedures were performed in office and health fair settings by nurses, medical assistants, or other trained personnel.

"This extensive real-world experience demonstrates that EsoGuard has advanced from an aspirational 'missing link' in esophageal cancer prevention to the linchpin of a clinically viable and scalable early detection program," said Lishan Aklog, Lucid's Chairman and Chief Executive Officer.

Lucid Diagnostics is a subsidiary of PAVmed Inc. (NASDAQ: PAVM) and focuses on cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer. The EsoGuard test and EsoCheck device are designed for early detection of esophageal precancer in at-risk patients.

You May Also Be Interested In